Soleno Therapeutics, Inc.

NasdaqCM SLNO

Soleno Therapeutics, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -13.98

Soleno Therapeutics, Inc. Price to Earnings Ratio (P/E) is -13.98 on January 14, 2025, a 67.49% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Soleno Therapeutics, Inc. 52-week high Price to Earnings Ratio (P/E) is -13.98 on January 14, 2025, which is 0.00% below the current Price to Earnings Ratio (P/E).
Soleno Therapeutics, Inc. 52-week low Price to Earnings Ratio (P/E) is -50.08 on February 27, 2024, which is -258.14% below the current Price to Earnings Ratio (P/E).
Soleno Therapeutics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -30.10.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: SLNO

Soleno Therapeutics, Inc.

CEO	Dr. Anish Bhatnagar M.D.
IPO Date	Nov. 13, 2014
Location	United States
Headquarters	203 Redwood Shores Parkway
Employees	33
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Key trends

Past 5 years